US-based programmable therapeutics developer Camp4 secured $45m yesterday from investors including conglomerate Kraft Group.
The round was co-led by 5AM Ventures and Northpond Ventures, while fellow venture capital firms Andreessen Horowitz and Polaris Partners also took part along with undisclosed existing backers.
Camp4 is developing programmable and precise therapeutics designed to treat a range of diseases including Dravet Syndrome and Urea cycle disorder. Its drug candidates target a class of ribonucleic acid (RNA) known as regulatory RNAs that control the expression of proteins.
The company will use the funding to expand its technology platform and advance multiple product candidates into human clinical trials.
The technology leverages research conducted by co-founders Richard Young, professor of biology at Massachusetts Institute of Technology’s Whitehead Institute, and Leonard Zon, professor of paediatric medicine at Harvard Medical School and director of the stem cell programme at Boston Children’s Hospital.
Andreessen Horowitz led Camp4’s $30m series A round in 2018, which included Kraft Group and Polaris Partners. The company also lists life sciences real estate investment trust Alexandria Real Estate Equities as an existing investor on its website.